Samsung Bioepis Presents Phase 1 and 3 Clinical Results for SB16, a Proposed Biosimilar to Proliaⁱ (denosumab), at ASBMR 2023
15 oct. 2023 19h00 HE
|
Samsung Bioepis
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced denosumab in healthy male study...
Samsung Bioepis Presents Two Abstracts at EADV 2023 Congress, Highlighting Continuous Dedication in Dermatology
11 oct. 2023 03h00 HE
|
Samsung Bioepis
Phase 3 study for SB17, Samsung Bioepis’ ustekinumab biosimilar candidate, demonstrates biosimilarity with reference ustekinumab through equivalent efficacy and comparable safety and pharmacokinetics...
Samsung Bioepis Releases Fourth Quarter 2023 US Biosimilar Market Report to Provide the Latest US Market Biosimilar Trends
10 oct. 2023 02h00 HE
|
Samsung Bioepis
Details the latest quarterly information on biosimilar utilization and financial datapoints for the US biosimilar marketExplores key determinants influencing various degrees of biosimilar utilization ...
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Clinical Trial for SB15, a Proposed Biosimilar to Eyleaⁱ (Aflibercept), at EURETINA 2023
07 oct. 2023 11h00 HE
|
Samsung Bioepis
Switching study conducted to evaluate whether switching from reference aflibercept to SB15 maintains comparable clinical efficacy and safetyPost-hoc analysis demonstrates biosimilarity between SB15...
Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate
11 sept. 2023 01h15 HE
|
Samsung Bioepis
Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America Partnership to support Samsung Bioepis pipeline expansion and provide increased...
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
01 août 2023 07h00 HE
|
Samsung Bioepis
INCHEON, South Korea and JERSEY CITY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability...
Samsung Bioepis Releases its Second US Biosimilar Market Report
11 juil. 2023 07h00 HE
|
Samsung Bioepis
Details updated average sales price (ASP) trends and market share across all molecules for which biosimilars are availableIncludes Wholesale Acquisition Cost (WAC) trends of recently launched...
Samsung Bioepis Releases 2023 Sustainability Report
30 juin 2023 02h00 HE
|
Samsung Bioepis
Highlights key initiatives that will drive the company’s transition towards a more sustainable businessReaffirms commitment to environmentally and socially responsible practices in R&D, clinical...
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
24 avr. 2023 18h30 HE
|
Samsung Bioepis
SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56Switching group had similar efficacy and safety compared to the...
Samsung Bioepis to Present New Data for SB15, a proposed biosimilar to Eylea (aflibercept), at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
20 avr. 2023 07h00 HE
|
Samsung Bioepis
Final 56-week results from the Phase 3 study for SB15 compared with reference aflibercept in neovascular age-related macular degeneration to be presented, in addition to analytical similarity data...